<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593241</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 01/10</org_study_id>
    <secondary_id>34569</secondary_id>
    <secondary_id>2011-005840-87</secondary_id>
    <nct_id>NCT01593241</nct_id>
  </id_info>
  <brief_title>Therapy De-escalation in Seminoma Stage IIA/B</brief_title>
  <official_title>Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to test the efficacy and safety of carboplatin
      chemotherapy and involved node radiotherapy in patients with stage IIA/B seminoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION AND BACKGROUND

        1. Disease background

           Testicular cancers are the most common malignancies in men aged between 18-35 years. Of
           those, seminoma is the most frequent as it accounts for about half of all testicular
           cancers. Seminoma is classified according to the involvement of and degree of spreading
           to lymph nodes and to the lung or other organs. Around 10% of all seminoma patients are
           diagnosed with stage IIA/B disease. Stage IIA patients have one or more enlarged
           regional lymph nodes, 2 cm or less in greatest dimension, without evidence of distant
           disease (cN1 cM0). Stage IIB patients have one or more enlarged regional lymph nodes
           more than 2 cm but not more than 5 cm in greatest dimension, without evidence of distant
           disease (cN2 cM0). Paraaortic, interaortocaval, para-/pre-/retrocaval and
           pre-/retroaortic lymph nodes are considered regional. Intrapelvic, external iliac and
           inguinal lymph nodes are considered regional only after scrotal or inguinal surgery.

           Seminoma stage IIA/B is highly responsive to chemotherapy or radiation therapy and the
           progression free survival at 5 or 6 years with such treatments is between 87-95%.
           Supra-diaphragmatic lymph nodes are the usual site of tumor recurrence after radiation
           therapy, while local failure or tumor persistence in paraaortic lymph nodes is
           predominant after chemotherapy.

        2. Therapy background

           Current standard of therapy in patients with stage IIA/B seminoma involves either large
           volume paraaortic and ipsilateral pelvic radiation therapy (&quot;dogleg field&quot;) or three
           cycles of chemotherapy with BEP (Bleomycin, Etoposide, Cisplatin). While both treatment
           modalities offer high rates of progression free survival and overall survival, they also
           potentially bear the risk of unwanted events during and following the treatment. Large
           volume radiation therapy is associated with fatigue, nausea and vomiting during
           treatment. BEP chemotherapy causes transient fatigue, cytopenia and hair loss. In terms
           of late adverse events, radiotherapy increases the risk for permanent kidney and bowel
           damage, while BEP chemotherapy may harm kidneys, lungs, heart and the inner ear. Both
           therapy modalities may also lead to secondary tumors. Data on late undesirable effects
           of large field radiation therapy or intensive chemotherapy will become available in the
           future at the conclusion of long term follow-up analyses of the recent trials. Thus, the
           current research on seminoma focuses on minimizing short and long term treatment-related
           morbidity.

        3. Previous trials

           Therapy de-escalation has been tested and been proven effective in stage I testicular
           seminoma patients. For many years, the standard of care for these patients was
           paraaortic radiation therapy. The trial by Oliver et al. demonstrated the
           non-inferiority of single dose carboplatin chemotherapy in comparison to paraaortic
           irradiation in terms of tumor control in patients with stage I seminoma. Although the
           trial did not present long term data and the demonstration of a lower toxicity profile
           with carboplatin compared to paraaortic irradiation is still lacking, many clinicians
           have already switched their treatment strategy to carboplatin chemotherapy in seminoma
           stage I patients, in hope that this treatment will produce less negative late effects
           than radiation therapy. Based on these results, we think that a similar therapy
           de-escalation approach could be attractive in patients with stage II disease.

        4. Rationale for performing the trial

      Therapy de-escalation for stage IIA/B seminoma has been recently tested in a prospective
      phase II trial with the use of 3 cycles (for stage IIA) or 4 cycles (for stage IIB) of
      carboplatin chemotherapy. However, this regime is actually not considered an acceptable
      treatment because of a relapse rate of 18% at three years. In this trial, all relapsed
      patients experienced tumor recurrence in the lymph nodes that were initially involved within
      3 years following treatment. Thus, while chemotherapy de-escalation with carboplatin leads to
      a good systemic disease's control, the local control in the involved nodes remains a problem.

      On the other hand, no relapse occurs in the initially involved lymph nodes in seminoma IIA/B
      patients which were treated with large volume irradiation, although 5% of the patients
      developed distant relapses.

      Therefore, one possible way to raise progression free survival in the involved lymph nodes
      areas to an acceptable level in a therapy de-escalation protocol would be to combine
      suboptimal carboplatin chemotherapy (1 cycle) with a limited volume of radiation therapy
      targeting the involved nodes (30 or 36 Gy for stage IIA or IIB, respectively).

      It is expected that this combination will trigger less side effects than any of the standard
      therapies. Previous trials demonstrated that single agent carboplatin is not associated with
      an increase in the number of adverse events for up to 9 years post chemotherapy. The
      application of small volume, involved node radiation therapy should avoid damage to viscera
      and kidneys. Furthermore, the risk for secondary malignancies will likely be reduced because
      of the low-intensity chemotherapy and dramatically shrunk irradiation field.

      This is a single arm trial, in which both stage IIA and IIB patients are included, since all
      current international treatment recommendations are valid for both disease stages. Selecting
      exclusively one disease stage for trial inclusion would greatly hamper the feasibility of
      such a trial.

      The trial design, trial treatment and trial specifics are a consensus among the Swiss
      Urogenital Tumors Project Group, the Swiss Radio-oncology Section and the German Testicular
      Cancer Study Group.

      If the proposed therapy scheme proves to be effective and safe, it will provide a
      significantly relevant treatment alternative to large volume radiotherapy and intense
      chemotherapy, and may become the new standard of care for patients with seminoma stage IIA/B.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2012</start_date>
  <completion_date type="Anticipated">September 2038</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>at 3 years</time_frame>
    <description>PFS is defined as the time from registration until one of the following events occurs:
PD or relapse, defined as progression according to the modified trial-specific version of RECIST 1.1 or a rising level of the tumor marker beta-hCG over the ULN (value must be confirmed by a second measurement). Presence of non-seminoma germ cell tumor has to be excluded in the latter case.
Death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) temporarily associated with the trial treatment</measure>
    <time_frame>at 3 years</time_frame>
    <description>AEs are collected from inclusion until 30 days after the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late AEs</measure>
    <time_frame>at the latest at 20 years</time_frame>
    <description>AEs will be collected from 30 days after the end of treatment until the end of the follow-up phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary malignancies</measure>
    <time_frame>at the latest at 20 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>at 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>at the latest at 20 years</time_frame>
    <description>from registration until documented progressive disease, relapse or death due to tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at the latest at 20 years.</time_frame>
    <description>from registration to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seminoma specific survival</measure>
    <time_frame>at the latest at 20 years</time_frame>
    <description>from registration to the date of death due to seminoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>at the latest at 20 years</time_frame>
    <description>from registration to the date of failure of PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Localization of progression</measure>
    <time_frame>at the latest at 20 years</time_frame>
    <description>from first localization where recurrent tumor disease is detected</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Seminoma</condition>
  <arm_group>
    <arm_group_label>Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy</description>
    <arm_group_label>Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Involved node RT</intervention_name>
    <description>Involved node RT</description>
    <arm_group_label>Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has given written informed consent before registration.

          -  Histologically confirmed classical seminoma treated with primary inguinal
             orchidectomy.

          -  Tumor stage at diagnosis or at relapse after primary active surveillance is pT1-4*
             cN1-2 cM0 according to UICC TNM 2009 is pT1-4 cN1-2 cM0 according to UICC TNM 2009.

          -  Multi-slice CT or MRI or FDG-PET-CT of the chest, abdomen and pelvis or a FDG-PET-CT
             within 4 weeks prior to patient registration, showing stage IIA/B disease. I.v.
             contrast medium has to be administered.

          -  Age ≥ 18 years.

          -  WHO performance status 0-2.

          -  Adequate hematological values: neutrophils ≥ 1.0 x 109/L, platelets ≥ 100x 109/L.

          -  Adequate renal function (calculated creatinine clearance ≥ 50 ml/min, according to the
             formula of Cockcroft-Gault).

          -  Patient agrees not to father a child during trial treatment and during 12 months
             thereafter.

          -  Patient has been proposed sperm conservation.

          -  Patient compliance and geographic proximity allow proper staging and follow-up for at
             least 3 years.

        Exclusion Criteria:

          -  Previous or concurrent malignancy within 5 years with the exception of localized
             non-melanoma skin cancer or stage I seminoma for patients entering the trial with
             relapse during active surveillance.

          -  Psychiatric disorder precluding understanding of information on trial-related topics
             or giving informed consent or interfering with compliance for treatment schedule.

          -  Mixed histology seminoma.

          -  Elevated levels of AFP (≥ULN) at any time.

          -  Any prior abdominal/pelvic radiotherapy (RT).

          -  Any anti-cancer therapy after primary tumor resection (active surveillance for stage I
             disease is not considered as a treatment).

          -  Any treatment in a clinical trial within 30 days of trial entry.

          -  Any serious underlying medical condition or serious co-morbidity (at the judgment of
             the investigator) which could impair the ability of the patient to participate in the
             trial.

          -  Any contraindication for the trial drug (for example, known hypersensitivity to trial
             drug or to any other co-component of the trial drug, past or current renal
             insufficiency, severe hepatic insufficiency, severe bone marrow dysfunction, tumor
             bleeding, major hearing defects).

          -  Any concomitant drugs contraindicated for use with the trial drug according to the
             approved product information (for example, nephrotoxic or ototoxic medicines).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandros Papachristofilou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Cathomas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital Graubünden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Bedke, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>D - University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandros Papachristofilou, MD</last_name>
    <phone>+41 61 265 49 46</phone>
    <email>apapachristofilou@uhbs.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Corinne Schär, PhD</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aachen Universitätsklinik</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Berlin Universitätsklinik Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Busch, MD</last_name>
      <phone>+49 30 450 515095</phone>
      <email>jonas.busch@charite.de</email>
    </contact>
    <investigator>
      <last_name>Jonas Busch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berlin Vivantes - Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Dieing, Prof</last_name>
      <phone>+49 30 130 222152</phone>
      <email>annette.dieing@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Annette Dieing, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berlin Vivantes - Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Wit, Prof</last_name>
      <phone>+49 30 130 142251</phone>
      <email>maike.dewit@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Maike de Wit, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorch Anja, Prof</last_name>
      <phone>+49 211 810 8138</phone>
      <email>anja.lorch@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Anja Lorch, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Krege, Prof</last_name>
      <phone>+49 201 174 29 003</phone>
      <email>s.krege@kliniken-essen-mitte.de</email>
    </contact>
    <investigator>
      <last_name>Susanne Krege, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamburg Universitätsklinikum - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Oechsle, MD</last_name>
      <phone>+49 40 741 050667</phone>
      <email>k.oechsle@uke.uni-hamburg.de</email>
    </contact>
    <investigator>
      <last_name>Karin Oechsle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krefeld Maria-Hilf Krankenhaus</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Herden, MD</last_name>
      <phone>+49 221 478 82112</phone>
      <email>jan.herden@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Jan Herden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Harlaching</name>
      <address>
        <city>München</city>
        <zip>81545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xaver Schiel, Prof</last_name>
      <phone>+49 89 6210 2731</phone>
      <email>xaver.schiel@klinikum-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Xaver Schiel, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Bedke, Prof</last_name>
      <phone>+49 (7071) 2980349</phone>
      <email>jens.bedke@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Jens Bedke, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedemann Zengerling, MD</last_name>
      <phone>+49 731 500 58036</phone>
      <email>friedemann.zengerling@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Friedemann Zengerling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Wehrhahn, MD</last_name>
      <phone>+41 62 838 59 27</phone>
      <email>tobias.wehrhahn@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Tobias Wehrhahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammo Bartnick, MD</last_name>
      <phone>+41 56 486 27 62</phone>
      <email>tammo.bartnick@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Tammo Bartnick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandros Papachristofilou, MD</last_name>
      <phone>+41 61 265 49 46</phone>
      <email>apapachristofilou@uhbs.ch</email>
    </contact>
    <investigator>
      <last_name>Alexandros Papachristofilou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana (IOSI)</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ngwa Che Azinwi, MD</last_name>
      <phone>+41 91 811 89 32</phone>
      <email>ngwache.azinwi@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Ngwa Che Azinwi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Aebersold, Prof</last_name>
      <phone>+41 31 632 24 31</phone>
      <email>daniel.aebersold@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Aebersold, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Aebersold, MD</last_name>
      <phone>+41 31 632 24 31</phone>
      <email>daniel.aebersold@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Aebersold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Cathomas, MD</last_name>
      <phone>+41 81 256 66 95</phone>
      <email>richard.cathomas@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Richard Cathomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Berthold, MD</last_name>
      <phone>+41 21 314 80 83</phone>
      <email>dominik.berthold@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Dominik Berthold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Mingrone, MD</last_name>
      <phone>+41 62 311 42 41</phone>
      <email>wmingrone_ol@spital.ktso.ch</email>
    </contact>
    <investigator>
      <last_name>Walter Mingrone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Sion</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaouthar Khanfir, MD</last_name>
      <phone>+41 27 603 87 72</phone>
      <email>kaouthar.khanfir@rsv-gnw.ch</email>
    </contact>
    <investigator>
      <last_name>Kaouthar Khanfir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludwig Plasswilm, MD</last_name>
      <phone>+41 71 494 22 32</phone>
      <email>ludwig.plasswilm@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Ludwig Plasswilm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regionalspital Thun</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Aebersold, Prof</last_name>
      <phone>+41 31 632 24 31</phone>
      <email>daniel.aebersold@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Aebersold, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Fischer, MD</last_name>
      <phone>+41 52 266 40 87</phone>
      <email>natalie.fischer@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Natalie Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.sakk.ch</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seminoma IIA/B</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>RT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seminoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

